San Francisco startup Structure Therapeutics can be focusing on an oral, once-day by day GLP-one drug identified as GSBR-1290—the drug surpassed Wall Street’s expectations in June any time a mid-phase examine showed regular weight loss of all-around six% and it programs to begin anot